Press Releases
Celator Pharmaceuticals completes enrollment in a second phase 2 trail of CPX-351in acute myeloid leukemia
Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive...
News
AstraZeneca initiates phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis
AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with...
News
Cipla launches the world’s first generic Pirfenidone in India
Cipla, among the world's leading generic pharmaceutical companies has introduced Pirfenidone in India; under the brand name Pirfenex, for the treatment of IPF. A...
Articles
Bringing in the Green
A Green mind-set can lead to a black bottom line. Becoming environmentally friendly can help boost brand image and ROI—and pharma can get there...
Press Releases
Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients With CF and Pancreatic Insufficiency
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical...
Industry Reports
ICON reports revenues of $225 million up 2% on prior year
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, reported its financial results for the third quarter...
Press Releases
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read